rolvedon
rolvedon: developed by 2 companies · 1 FDA decision. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Assertio Holdings, Inc. (ASRT) | Approved |
| SPECTRUM PHARMACEUTICALS INC (SPPI) | Approved |
FDA Decisions
Frequently asked questions
Who is developing rolvedon?
rolvedon is being developed by Assertio Holdings, Inc., SPECTRUM PHARMACEUTICALS INC.
What is rolvedon's latest FDA decision?
The most recent tracked FDA decision for rolvedon is Approval for 1 INDICATIONS AND USAGE Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. Rolvedon is a leukocyte growth factor indicated to decrease th, dated September 9, 2022.
Get deeper analysis on rolvedon
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis